



Published in final edited form as:

*J Leukoc Biol.* 2019 July ; 106(1): 27–34. doi:10.1002/JLB.4MIA1018-409R.

## IFN- $\gamma$ -Dependent Nitric Oxide Suppresses *Brucella*-Induced Arthritis by Inhibition of Inflammasome Activation

Carolyn A. Lacey<sup>\*,†</sup>, Catherine A. Chambers<sup>\*,†</sup>, William J. Mitchell<sup>\*</sup>, and Jerod A. Skyberg<sup>\*,†,‡</sup>

<sup>\*</sup>Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Missouri, Columbia, Missouri, 165211

<sup>†</sup>Laboratory for Infectious Disease Research, University of Missouri, Columbia, Missouri, 65211

### Abstract

Brucellosis, caused by the intracellular bacterial pathogen *Brucella*, is a globally important zoonotic disease for which arthritis is the most common focal complication in humans. Wild-type mice infected systemically with *Brucella* typically do not exhibit arthritis, but mice lacking IFN- $\gamma$  develop arthritis regardless of the route of *Brucella* infection. Here we investigated mechanisms by which IFN- $\gamma$  suppresses *Brucella*-induced arthritis. Several cell types, including innate lymphoid cells, contributed to IFN- $\gamma$  production and suppression of joint swelling. IFN- $\gamma$  deficiency resulted in elevated joint IL-1 $\beta$  levels, and severe joint inflammation that was entirely inflammasome dependent, and in particular, reliant on the NLRP3 inflammasome. IFN- $\gamma$  was vital for induction of the nitric oxide producing enzyme, iNOS, in infected joints, and nitric oxide directly inhibited IL-1 $\beta$  production and inflammasome activation in *Brucella*-infected macrophages *in vitro*. During *in vivo* infection, iNOS deficiency resulted in an increase in IL-1 $\beta$  and inflammation in *Brucella* infected joints. Collectively, this data indicate that IFN- $\gamma$  prevents arthritis both by limiting *Brucella* infection, and by inhibiting excessive inflammasome activation through the induction of nitric oxide.

### Abstract


**Summary Sentence:** IFN- $\gamma$  suppresses inflammation both by limiting *Brucella* infection, and by inhibiting excessive inflammasome activation through the induction of nitric oxide.

### Graphical Abstract

<sup>‡</sup>Corresponding author, Jerod A. Skyberg, Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Missouri, Columbia. skybergj@missouri.edu.

**Authorship:** CAL conceived the project, designed and performed experiments, and wrote the paper. CAC performed experiments. WJM scored histology slides. JAS conceived the project, and edited the paper.

**Conflict of Interest Disclosure:** The authors declare no conflicts of interest



## Keywords

brucellosis; innate lymphoid cell; NLRP3; caspase-1

## Introduction

Brucellosis, caused by the genus *Brucella*, is one of the most common zoonotic infections worldwide infecting over 500,000 individuals each year.<sup>1,2</sup> Transmission typically occurs through consumption of unpasteurized dairy goods or inhalation of aerosols from contaminated animal products.<sup>3,4</sup> Osteoarticular and/or musculoskeletal inflammation are the most common focal complications of brucellosis, with an incidence of 40–80% in infected patients.<sup>5,6</sup> Active infection of the joints is thought to be required for arthritis development, as viable brucellae are found within the synovial fluid of infected patients along with polymorphonuclear and mononuclear leukocytes.<sup>6–9</sup> *Brucella* induced arthritis is typically treated with prolonged antibiotic therapy; however, the time to resolution is often extensive, and disease can relapse.<sup>6,10</sup>

Wild-type (WT) mice infected with *Brucella* through systemic routes typically do not develop arthritis, however we reported IFN- $\gamma^{-/-}$  mice develop arthritis and musculoskeletal inflammation regardless of the route of *Brucella* infection.<sup>11</sup> It is currently unknown if IFN- $\gamma$  prevents arthritis by limiting *Brucella* dissemination to the joints, and/or if IFN- $\gamma$  acts locally in the joint to restrict infection and inflammation.<sup>12</sup> Many studies, including our own<sup>11,12</sup>, have demonstrated IFN- $\gamma$  is needed for resistance to brucellosis, however it is not clear what innate cells contribute to early IFN- $\gamma$  production, particularly at focal sites of infection such as the joint. In addition to T cells and NK cells, there has been an increase in reports indicating tissue resident cells, such as innate lymphoid cells (ILCs), can rapidly produce IFN- $\gamma$  to protect the host against infection.<sup>13,14</sup>

Recently we reported that inflammasomes induce joint inflammation, but also contribute to control of infection during *Brucella*-induced arthritis.<sup>15</sup> Inflammasomes are multi-protein structures that use sensors, such as NLRP3 and AIM2, to detect intracellular, cytosolic threats.<sup>16</sup> Upon sensor activation, canonical inflammasomes recruit pro-caspase-1, and cleave it into its functional form, caspase-1. Activated caspase-1 proteolytically activates IL-1 $\beta$  and IL-18 into their functional/secreted forms, and also induces pyroptosis, a pro-inflammatory cell death.<sup>16</sup> We recently showed that *Brucella* is also recognized by the non-canonical, inflammasome, caspase-11, which is activated by cytosolic LPS.<sup>15,17</sup> Caspase-11

does not directly cleave IL-1 $\beta$  or IL-18 into their active forms, but like caspase-1, can induce pyroptosis.<sup>18</sup> While inflammasomes can restrict infection, unregulated inflammasome activation can lead to immunopathology.<sup>15,19</sup> Here, we investigated cell types that contribute to the protective effects of IFN- $\gamma$  within the joint, and examined mechanisms by which inflammasome-dependent pathology is regulated by IFN- $\gamma$ .

## Materials and Methods

### Bacteria

*Brucella melitensis* 16M was grown on brucella agar (Ba) at 37°C (Becton Dickinson). Colonies were picked from Ba plates and cultured in brucella broth (Becton Dickinson) overnight at 37°C. Overnight *Brucella* concentration was estimated by measuring optical density at 600 nm, and inoculum was diluted to the appropriate concentration in sterile phosphate-buffered saline (PBS). Actual viable titer was confirmed by dilution of inoculum onto Ba.

### Mice

Experiments were conducted using 6- to 12-week-old age- and sex-matched mice on a C57BL/6J background. Rag1<sup>-/-</sup>, Caspase-1/11<sup>-/-</sup>, NLRP3<sup>-/-</sup>, AIM2<sup>-/-</sup>, Caspase-11<sup>-/-</sup>, and NOS2<sup>-/-</sup> mice were obtained from Jackson Laboratory. IL-1R<sup>-/-</sup>/IL-18<sup>-/-</sup> mice were obtained from the University of North Carolina. Mice were infected in each rear footpad with 50  $\mu$ l of PBS containing 1 $\times$ 10<sup>5</sup> CFU of *Brucella*/footpad,<sup>20</sup> or intraperitoneally (i.p.) with 1 $\times$ 10<sup>5</sup> CFU of *Brucella* in 200  $\mu$ l of PBS.<sup>11,15</sup> All studies were conducted in accordance with University of Missouri Animal Care and Use Committee guidelines. To neutralize IFN- $\gamma$  during footpad infection, mice were treated i.p. with 0.5 mg anti-IFN- $\gamma$  (clone XMG1.2, BioXCell) 1 day prior to, and 3 days after infection. Control mice received Rat IgG (Southern Biotech). To neutralize IFN- $\gamma$  during i.p. infection, mice were treated i.p. with 0.25 mg anti-IFN- $\gamma$  1 day prior to infection, and 3 times a week thereafter.<sup>12</sup> Rag1<sup>-/-</sup> mice were treated with 0.2 mg of anti-NK1.1 (clone PK136) or anti-CD90.2 (clone 30H12), on days -1, 2, and 5 in relation to infection,<sup>21</sup> to deplete these mice of NK cells, or ILCs respectively.

### Joint processing for bacterial burdens and cytokine measurements

Spleens and joints (following removal of skin) were mechanically ground in PBS.<sup>15</sup> Serial dilutions of homogenates were plated onto Ba and CFUs/tissue calculated. Cytokines were measured via Luminex (Millipore) or ELISA (Invitrogen) according to manufacturer's instructions. Cytokine data was normalized to total protein by BCA (Thermo Scientific).

### Macrophage infections

Bone marrow derived macrophages (BMDMs) were generated with M-CSF in complete media (CM: RPMI 1640 containing HEPES, sodium pyruvate, non-essential amino acids, and 10% FBS).<sup>15</sup> For Western blots, BMDMs were infected in CM with 2% FBS, while all other infections utilized CM with 10% FBS. BMDMs were infected with *B. melitensis* at a multiplicity of infection (MOI) of 100 for 6 hours, washed, incubated in CM with 50  $\mu$ g/ml gentamicin for 0.5 hours, washed, and then incubated in CM containing 2.5  $\mu$ g/ml of

gentamicin for the remainder of the experiment. To determine bacterial burdens, BMDMs were washed, lysed in H<sub>2</sub>O and plated onto Ba.

### Immunoblots

24 hours after infection, BMDMs were lysed in RIPA buffer (Thermo), and total protein normalized using BCA. Supernatants and lysates were probed with anti-Caspase-1 p20 (casper-1, Adipogen) and then peroxidase-conjugate Goat Anti-Mouse IgG (Jackson Immuno Research). Detection was performed with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo).

### RT-PCR

Joints were homogenized in TRI reagent, and RNA was isolated according to manufacturer's instructions (Sigma). RNA was further purified on an RNeasy column (Qiagen). cDNA was generated using the superscript III First Strand Synthesis System (Invitrogen) using oligodT primers. Relative iNOS mRNA in relation to GAPDH was quantified by measuring SYBR green incorporation using the comparative threshold method.<sup>22</sup>

### Assessment of Pathology

Basal joint measurements were made prior to infection. Joint swelling was determined by collective measurement of tibiotarsal joints following footpad infection, or by collective measurement of tibiotarsal and radiocarpal joints for i.p. infections, in relation to basal values. For histology, H&E sections from tibiotarsal joints were scored from 0–4 as previously detailed.<sup>[20]</sup>

### Flow cytometry

Rear ankle joints were processed with collagenase/DNAse as described<sup>15</sup> and cells were acquired on a CyAn ADP Analyzer (Beckman Coulter) or LSR Fortessa (Becton Dickinson). FlowJo (Tree Star) software was used for analysis. Immunofluorescence staining was performed using the following fluorochrome-labeled monoclonal antibodies from eBioscience or BioLegend: F4/80 (BM8), Ly-6G (1A8), CD11b (M1/70), CD45.2 (104), CD90.2 (30H12), NK1.1 (PK136), TCR $\gamma\delta$  (UC7–13D5).

### Statistics

Statistical analysis of the difference between 2 mean values was conducted using a two-tailed Student t test with significance at P < .05, while comparisons of 3 mean values was done using ANOVA, followed by Tukey's test with significance at P < .05. Differences in histology scores were determined by ANOVA on ranks.

### Online supplemental material

Supplementary Figure 1 depicts the effects of; IFN- $\gamma$  deficiency on neutrophil recruitment, NK cell or  $\gamma\delta$  T cell depletion on joint swelling, IFN- $\gamma$  production, and control of infection, and the effect of ILC depletion on iNOS transcription in infected joints. Confirmation of depletion of NK cells,  $\gamma\delta$  T cells, and ILCs is also shown in Supplementary Figure 1. The effects of IL-18/IL-1R, AIM2, Caspase-11, and the NLRP3 inhibitor, MCC950, on joint

swelling in IFN- $\gamma$  deficient mice is shown in Supplementary Figure 2. In addition, Supplementary Figure 2, shows iNOS-dependent NO production by *Brucella*-infected macrophages stimulated with IFN- $\gamma$ , NO levels in SNAP treated macrophage cultures, and the effect of the iNOS inhibitor, AGHS on joint inflammation.

## Results and Discussion

### ILCs are required for IFN- $\gamma$ production and suppression of joint swelling in *Brucella* infected mice

We previously reported *Brucella* infection in IFN- $\gamma$ -deficient mice results in arthritis regardless of the route of infection.<sup>11</sup> However, it was unknown if IFN- $\gamma$  prevented arthritis by solely limiting *Brucella* dissemination to the joints, and/or if IFN- $\gamma$  acted locally in the joint to restrict infection and inflammation. To determine if IFN- $\gamma$  plays a local role during the development of *Brucella*-induced arthritis, we utilized a footpad model of *Brucella* infection.<sup>20</sup> Using this model, we found that *Brucella* infection in WT mice resulted in a robust increase in myeloid cells, and in particular neutrophils, within the joint (Figure S1A–B). However, neutralization of IFN- $\gamma$  in footpad infected WT mice enhanced neutrophil recruitment ~10 fold (Figure S1A–B), indicating that local IFN- $\gamma$  within the joint contributes to suppression of arthritis during *Brucella* infection.

Previously, we demonstrated lymphocytes were required for resolution of chronic joint infection and inflammation in mice infected in the footpad with *Brucella*.<sup>20</sup> To investigate whether lymphocytes contribute to the effect of IFN- $\gamma$  during *Brucella*-induced arthritis, we footpad infected WT and Rag1<sup>-/-</sup> (lymphocyte deficient) mice and treated them with an IFN- $\gamma$  neutralizing antibody or an isotype control. Joint swelling was measured and bacterial burdens were assayed at day 7 post-infection (Figure 1A–B). Lymphocytes did contribute to control of infection as IgG-treated Rag1<sup>-/-</sup> mice had increased joint *Brucella* burdens compared to IgG-treated WT animals (Figure 1A). The effect of lymphocytes appears to require IFN- $\gamma$ , as Rag1<sup>-/-</sup> mice treated with anti-IFN- $\gamma$  have similar bacterial burdens as WT-anti-IFN- $\gamma$  treated mice (Figure 1A). While the effect of lymphocytes on control of infection was IFN- $\gamma$ -dependent, cells other than lymphocytes contribute to the IFN- $\gamma$  response in the joint, as neutralization of IFN- $\gamma$  from Rag1<sup>-/-</sup> mice resulted in increased joint bacterial burdens and swelling compared to Rag1<sup>-/-</sup> mice treated with IgG (Figure 1A–B), and IFN- $\gamma$  was still detected in Rag1<sup>-/-</sup> joints treated with IgG (Figure S1D). Anti-IFN- $\gamma$  treated Rag1<sup>-/-</sup> mice also had reduced joint swelling relative to anti-IFN- $\gamma$  treated WT mice (Figure 1B), indicating that lymphocytes partially contribute to the joint swelling and inflammation that is observed in the absence of IFN- $\gamma$ .

We next investigated the role of innate sources of IFN- $\gamma$ . While both NK cells and  $\gamma\delta$  T cells can rapidly produce IFN- $\gamma$  in response to infection,<sup>23,24</sup> we found that depletion of NK cells or  $\gamma\delta$  T cells from WT mice did not alter joint swelling, IFN- $\gamma$  levels, or *Brucella* burdens (Figure S1E–G, I, J). Therefore, we investigated the effect of ILCs, which can be tissue resident innate sources of IFN- $\gamma$ .<sup>25</sup> To do this, we treated Rag1<sup>-/-</sup> mice with anti-NK1.1, to deplete NK cells, or with anti-CD90, to deplete all ILCs including NK cells.<sup>21</sup> ILC depletion was confirmed via flow cytometry (Figure S1K). By day 7 post-infection joint swelling in Rag1<sup>-/-</sup> mice depleted of ILCs was ~3 times higher than in NK cell-depleted

Rag1<sup>-/-</sup> mice (Figure 1C). In addition, joint IFN- $\gamma$  levels (Figure 1D) and mRNA expression of the nitric oxide producing enzyme iNOS (Figure S1H) were significantly reduced by ILC depletion. Surprisingly, despite having increased joint swelling, Rag1<sup>-/-</sup>, anti-CD90 treated mice actually had slightly reduced joint and spleen bacterial burdens compared to Rag1<sup>-/-</sup>, anti-NK1.1 treated animals (Figure 1E). These data suggest that while IFN- $\gamma$  protects the host by restricting *Brucella* infection, IFN- $\gamma$  may also suppress inflammation by mechanisms that are independent of bacterial clearance. Three major ILC populations have been described, (ILC1, ILC2, and ILC3).<sup>25</sup> While IFN- $\gamma$  production is a signature of ILC1 cells, recent studies have shown that ILC3 cells can also protect the host by producing IFN- $\gamma$ .<sup>26</sup> Future work will determine the relative contribution of ILC subsets to IFN- $\gamma$  production, and control of infection and arthritis during brucellosis.

### IFN- $\gamma$ deficiency results in caspase-1/11-dependent joint inflammation

*Brucella*-induced IL-1 $\beta$  production requires caspase-1,<sup>27</sup> and in an earlier study, we determined that both caspase-1 and caspase-11 contribute to joint inflammation during *Brucella* infection.<sup>15</sup> As we found that IFN- $\gamma$  deficiency resulted in markedly increased joint IL-1 $\beta$ , (Figure S1C), we investigated whether IFN- $\gamma$  restrains caspase-1/11 dependent inflammation. WT and caspase1/11<sup>-/-</sup> mice were footpad infected with *Brucella* and treated with anti-IFN- $\gamma$  or an isotype control. At day 7 post infection, we found mice deficient in either IFN- $\gamma$  or caspases-1 and 11 had increased *Brucella* burdens (Figure 2A). However, caspase-1/11<sup>-/-</sup> mice neutralized of IFN- $\gamma$  had significantly higher *Brucella* joint colonization than caspase-1/11<sup>-/-</sup> mice treated with IgG, indicating the protective effect of IFN- $\gamma$  on bacterial clearance is not entirely inflammasome dependent.

Neutralization of IFN- $\gamma$  from WT mice resulted in markedly enhanced joint swelling by day 3 post-infection and everyday thereafter (Figure 2B). In contrast, IFN- $\gamma$  neutralization in caspase-1/11<sup>-/-</sup> mice did not result in enhanced joint swelling (Figure 2B), or inflammation (Figure 2C–D), despite the fact that joints from anti-IFN- $\gamma$  treated caspase-1/11<sup>-/-</sup> mice had *Brucella* loads ~50 fold higher than joints from IgG-treated caspase-1/11<sup>-/-</sup> mice (Figure 2A). The finding that IFN- $\gamma$  neutralization enhances inflammation in WT, but not caspase-1/11<sup>-/-</sup> mice, indicates that the increased inflammation caused by IFN- $\gamma$  deficiency requires inflammasomes. In addition, neutralization of IFN- $\gamma$  from WT, but not caspase-1/11<sup>-/-</sup> mice resulted in increased joint IL-1 $\beta$  levels (Figure 2E), suggesting that IFN- $\gamma$  deficiency results in increased inflammasome activation. Enhanced caspase-1-dependent production of IL-1 and IL-18 in IFN- $\gamma$  deficient animals likely contributes to joint inflammation, as IL-18/IL-1R signaling appeared to play a larger role in joint swelling in IFN- $\gamma$  deficient animals than did caspase-11 (Figure S2A–B).

*Brucella* is known to activate caspase-1 via the AIM2 and NLRP3 inflammasomes.<sup>27,28</sup> In order to identify what inflammasome components contribute to arthritis, and if these phenotypes are altered by IFN- $\gamma$  deficiency, we treated WT and inflammasome deficient mice with anti-IFN- $\gamma$  or an isotype control during *Brucella* footpad infection. The AIM2 inflammasome was dispensable for joint swelling (Figure S2C) and control of infection (data not shown) in the presence or absence of IFN- $\gamma$ . NLRP3 contributed transiently to joint swelling in the presence of IFN- $\gamma$ , with NLRP3<sup>-/-</sup> mice displaying a reduction in

swelling only at day 2 post-infection (Figure 3A). Interestingly, in the absence of IFN- $\gamma$ , NLRP3 deficiency significantly reduced joint swelling at every timepoint measured (Figure 3B), without affecting *Brucella* burdens in the joint (data not shown). In addition, we found that treatment of IFN- $\gamma$  deficient animals with the NLRP3-specific inhibitor, MCC950,<sup>29</sup> resulted in decreased joint swelling in *Brucella*-infected mice (Figure S2D). Thus, these data indicate that the inflammasome-dependent joint pathology that occurs in the absence of IFN- $\gamma$  requires NLRP3.

To determine if the effect of inflammasomes/NLRP3 was limited to footpad infection, we measured arthritis in IFN- $\gamma$  neutralized WT, caspase-1/11<sup>-/-</sup> and NLRP3<sup>-/-</sup> mice infected i.p. with *B. melitensis*. NLRP3 and caspase1/11 deficiency resulted in significantly reduced joint swelling, while no differences in *Brucella* burdens in spleens or joints were observed at day 27 post-infection (Figure 3C–D). Thus, these data indicate that IFN- $\gamma$  prevents inflammasome/NLRP3 dependent joint pathology regardless of the route of infection.

While humans produce IFN- $\gamma$  during *Brucella* infection, chronic human brucellosis patients display an impaired IFN- $\gamma$  response to *Brucella* relative to patients at the onset of disease.<sup>30</sup> Human brucellosis patients are also more likely to have IFN- $\gamma$  gene polymorphisms associated with reduced IFN- $\gamma$  production.<sup>31</sup> Thus, impaired IFN- $\gamma$  production in these patients could lead to inflammasome-dependent pathology. Unregulated inflammasome activation in the absence of IFN- $\gamma$  could also lead to mortality. Indeed, one study in mice demonstrated T cell or IFN- $\gamma$  deficiency resulted in similarly elevated *Brucella* burdens following pulmonary infection; however, IFN- $\gamma$  deficient mice developed neutrophilia and succumbed to infection while T cell deficient mice do not.<sup>32</sup> This, coupled with our own data, suggests disease severity and mortality in IFN- $\gamma$  deficient mice is due to elevated bacterial burdens, but also due to overwhelming pathology, possibly caused by an inability to regulate inflammasome induced inflammation.

### IFN- $\gamma$ -Dependent Nitric Oxide Suppresses *Brucella*-induced inflammasome activation

Enhanced inflammasome-dependent pathology in the absence of IFN- $\gamma$  is likely due in part to higher bacterial loads in IFN- $\gamma$  deficient animals, which results in increased inflammasome activation. However, to explain why mice lacking ILCs had enhanced joint swelling, despite lower levels of *Brucella* and IFN- $\gamma$  (Figure 1C–E), we considered IFN- $\gamma$ , or effectors downstream of IFN- $\gamma$ , may be negatively regulating inflammasome activation. We found reduced iNOS transcript in ILC deficient mice (Figure S1H), which was of interest as IFN- $\gamma$  induced nitric oxide (NO) s-nitrosylates NLRP3 to suppress inflammasome activation during *Mycobacterium tuberculosis* infection.<sup>19</sup> As NLRP3 played a major role in joint pathology in *Brucella*-infected, IFN- $\gamma$  deficient mice (Figure 3B&C), we investigated the ability of IFN- $\gamma$ -dependent NO to suppress inflammasome activation and inflammation during *Brucella* infection.

IFN- $\gamma$  neutralization decreased iNOS mRNA transcript in *Brucella*-infected joints at day 2 post-infection (Figure 4A) and at later timepoints (data not shown). Addition of recombinant IFN- $\gamma$  to *Brucella* infected macrophages also resulted in NO production that could be blocked by the addition of the iNOS inhibitor, aminoguanidine hemisulfate salt (AGHS) (Figure S2E). To determine if iNOS was protective against *Brucella*-induced arthritis, we

administered AGHS, to the animals' drinking water, and compared these mice to those that received untreated water.<sup>19</sup> Mice receiving AGHS displayed increased joint inflammation, IL-1 $\beta$ , and *Brucella* burdens relative to animals receiving regular drinking water (Figure S2F–H). Next, we evaluated the relative ability of iNOS and IFN- $\gamma$  to control infection and suppress inflammasome-dependent IL-1 $\beta$  production in the joint. To do this, we footpad-infected, IgG-treated WT and iNOS deficient mice (NOS2<sup>-/-</sup>), and WT mice neutralized of IFN- $\gamma$ . As early as day 3 post-infection, IgG-treated NOS2<sup>-/-</sup> mice displayed increased joint swelling relative to WT, IgG-treated mice (Figure 4B). iNOS deficiency also resulted in slightly, but significantly increased joint *Brucella* burdens relative to WT animals at day 7 post-infection (Figure 4C). iNOS deficiency did not increase joint bacterial levels to the same degree as IFN- $\gamma$  deficiency. However, joint IL-1 $\beta$  levels were similarly elevated in NOS2<sup>-/-</sup> mice and IFN- $\gamma$  neutralized mice (Figure 4D) despite bacterial loads being ~100-fold lower in NOS2<sup>-/-</sup> animals relative to IFN- $\gamma$  deficient mice. These data indicate NO limits inflammasome-dependent inflammation and IL-1 $\beta$  production by mechanisms beyond simply restricting *Brucella* infection.

*Brucella* can infect a variety of phagocytic and non-phagocytic cells,<sup>33</sup> however within the joint we have found myeloid cells, and in particular macrophages are the major target of *Brucella* (unpublished observation). Therefore, we utilized bone-marrow derived macrophages to further elucidate the relationship between NO, IFN- $\gamma$  and inflammasome activation. To determine if NO can directly inhibit inflammasome activation during *Brucella* infection, BMDMs were treated with increasing doses of the NO donor, S-nitroso-N-acetylpenicillamine (SNAP). NO is potently bactericidal against *Brucella*.<sup>34</sup> Therefore, we treated macrophages with SNAP only after *Brucella* infection. Under these conditions, we found intracellular *Brucella* burdens were similar in vehicle and SNAP treated wells when cell lysates and supernatants were harvested 24 hours post-infection (Figure 4E). Administration of SNAP resulted in NO production (Figure S2I) and suppressed *Brucella*-induced IL-1 $\beta$  release into cell supernatant (Figure 4F). Western blots were then performed to confirm this effect was due to inhibition of caspase-1 activation. We demonstrated caspase-1 is activated by *B. melitensis* infection, as cleaved caspase-1 was found in the cell supernatant of infected, but not uninfected macrophages (Figure 4G). In addition, administration of SNAP reduced *Brucella*-induced caspase-1 activation, as supernatants from *Brucella* infected cells treated with SNAP contained reduced active caspase-1 relative to vehicle treated, infected cells (Figure 4G).

While it has long been known that IFN- $\gamma$  restricts *Brucella* infection, our data here show IFN- $\gamma$  also limits inflammation by inducing nitric oxide that in turn suppresses inflammasome activation and pathology. Human macrophages do not produce NO in response to IFN- $\gamma$  as robustly as do murine macrophages.<sup>35</sup> Thus, enhanced NO production relative to humans could be one of the factors that contributes to the resistance of wild-type mice to *Brucella*-induced arthritis. NO donors are well tolerated in humans.<sup>36</sup> In addition, NO is antimicrobial against *Brucella*<sup>37</sup> and we show here that NO can inhibit unregulated inflammasome-dependent pathology. Thus, NO donors and/or NLRP3 inhibitors, in combination with antibiotics, might be potential complementary therapeutic candidates to treat brucellosis, particularly in patients with impaired IFN- $\gamma$  production.



## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements:

This work was supported in part by the National Institutes of Health (NIH R21AI119634) and funding from the University of Missouri College of Veterinary Medicine and Research Board.. IL-1R<sup>-/-</sup>/IL-18<sup>-/-</sup> mice were a gift from Dr. Edward Miao at the University of North Carolina.

## Abbreviations:


<b>AGHS</b>	aminoguanidine hemisulfate salt
<b>AIM2</b>	absent in melanoma 2
<b>Ba</b>	brucella agar
<b>BCA</b>	bicinchoninic acid assay
<b>BMDMs</b>	bone marrow derived macrophages
<b>CFU</b>	colony forming unit
<b>CM</b>	complete media
<b>FBS</b>	fetal bovine serum
<b>GAPDH</b>	glyceraldehyde 3-phosphate dehydrogenase
<b>ILCs</b>	innate lymphoid cells
<b>iNOS</b>	inducible nitric oxide synthase
<b>i.p.</b>	intraperitoneal
<b>LPS</b>	lipopolysaccharide
<b>MOI</b>	multiplicity of infection
<b>NLRP3</b>	NACHT, LLR and PYD domains-containing protein 3
<b>NO</b>	nitric oxide
<b>PBS</b>	phosphate buffered saline
<b>SD</b>	standard deviation
<b>SNAP</b>	S-nitroso-N-acetyl-penicillamine
<b>WT</b>	wild-type

## References

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV 2006 The new global map of human brucellosis. *Lancet. Infect Dis.* 6:91–9. [PubMed: 16439329]


2. Colmenero JD, Reguera JM, Fernandez-Nebro A, Cabrera-Franquelo F 1991 Osteoarticular complications of brucellosis. *Ann. Rheum. Dis* 50:23–6. [PubMed: 1994863]
3. Zinsstag J, Roth F, Orkhon D, Chimed-Ochir G, Nansalmaa M, Kolar J, Vounatsou P 2005 A model of animal–human brucellosis transmission in Mongolia. *Prev. Vet. Med* 69:77–95. [PubMed: 15899298]
4. Kaufmann AF, Fox MD, Boyce JM, Anderson DC, Potter ME, Martone WJ, Patton CM 1980 Airborne spread of brucellosis. *Ann. NY Acad. Sci* 353:105–14. [PubMed: 6939379]
5. Rajapakse CN 1995 Bacterial infections: osteoarticular brucellosis. *Bailliere’s Clin. Rheum* 9:161–77.
6. Gotuzzo E, Alarcon GS, Bocanegra TS, Carrillo C, Guerra JC, Rolando I, Espinoza LR 1982 Articular involvement in human brucellosis: a retrospective analysis of 304 cases. *Semin. Arthritis. Rheum* 112:245–55.
7. Martin-Hernandez CB-JJ, Espallargas-Doñate T, Fuertes-Vallcorba A. 2009 Arthroscopic synovectomy, an alternative in the treatment of brucellar arthritis of the knee with prolonged course. A report of two cases. *Int. J Orthopedic. Surg* 13.
8. Khateeb MI, Araj GF, Majeed SA, Lulu AR 1990 Brucella arthritis: a study of 96 cases in Kuwait. *Ann. Rheum. Dis* 49:994–8. [PubMed: 2270973]
9. Press J, Peled N, Buskila D, Yagupsky P 2002 Leukocyte count in the synovial fluid of children with culture-proven brucellar arthritis. *Clin. Rheum* 21:191–3.
10. Aya lio lu E, Özlük Ö, Kılıç D, Kaygusuz S, Kara S, Aydın G, Çokca F, Tekeli E A case of brucellar septic arthritis of the knee with a prolonged clinical course. *Rheumatol. Internat* 25:69–71.
11. Skyberg JA, Thornburg T, Kochetkova I, Layton W, Callis G, Rollins MF, Riccardi C, Becker T, Golden S, Pascual DW 2012 IFN-gamma-deficient mice develop IL-1-dependent cutaneous and musculoskeletal inflammation during experimental brucellosis. *J. Leukoc. Biol* 92:375–87. [PubMed: 22636321]
12. Lacey CA, Keleher LL, Mitchell WJ, Brown CR, Skyberg JA 2016 CXCR2 Mediates Brucella-Induced Arthritis in interferon gamma-Deficient Mice. *J.Infect. Dis* 214:151–160. [PubMed: 26951819]
13. Weizman O-E, Adams NM, Schuster IS, Krishna C, Pritykin Y, Lau C, Degli-Esposti MA, Leslie CS, Sun JC, O’Sullivan TE 2017 ILC1 confer early host protection at initial sites of viral infection. *Cell*. 171:795–808. [PubMed: 29056343]
14. Abt MC, Lewis BB, Caballero S, Xiong H, Carter RA, Sušac B, Ling L, Leiner I, Pamer EG 2015 Innate immune defenses mediated by two ILC subsets are critical for protection against acute *Clostridium difficile* infection. *Cell Host Microb*. 18:27–37.
15. Lacey CA, Mitchell WJ, Dadelahi AS, Skyberg JA (2018) 2018. Caspase-1 and caspase-11 mediate pyroptosis, inflammation, and control of Brucella joint infection. *Infect. Immun* 86(9). e00361–18. [PubMed: 29941463]
16. Rathinam VA and Fitzgerald KA 2016 Inflammasome Complexes: Emerging Mechanisms and Effector Functions. *Cell*. 165:792–800 [PubMed: 27153493]
17. Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA (2013) 2013. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. *Science* 341:1250–3. [PubMed: 24031018]
18. Kayagaki N, Warming S, Lamkanfi M, Walle LV, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S 2011 Non-canonical inflammasome activation targets caspase-11. *Nature*. 479:117. [PubMed: 22002608]
19. Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, Sasseti CM 2013 Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. *Nat. Immunol* 14:52–60. [PubMed: 23160153]
20. Lacey CA, Mitchell WJ, Brown CR, Skyberg JA 2017 Temporal Role for MyD88 in a model of Brucella-induced arthritis and musculoskeletal inflammation. *Infect. Immun* 85(3)e00961–16. [PubMed: 28069819]
21. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA, Angelosanto JM, Laidlaw BJ, Yang CY, Sathaliyawala T 2011 Innate lymphoid cells promote lung-tissue

- homeostasis after infection with influenza virus. *Nat. Immunol* 12:1045–1054. [PubMed: 21946417]
22. Schmittgen TD and Livak KJ 2008 Analyzing real-time PCR data by the comparative C(T) method. *Nat. Protoc* 3:1101. [PubMed: 18546601]
  23. Skyberg JA, Thornburg T, Rollins M, Huarte E, Jutila MA, Pascual DW 2011 Murine and bovine gammadelta T cells enhance innate immunity against *Brucella abortus* infections. *PloS One*. 6:e21978. [PubMed: 21765931]
  24. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP 1999 Natural killer cells in antiviral defense: function and regulation by innate cytokines. *Ann. Rev. Immunol* 17:189–220. [PubMed: 10358757]
  25. Klose CS and Artis D 2016 Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. *Nat. Immunol* 17:765–774. [PubMed: 27328006]
  26. Seo GY, Shui JW, Takahashi D, Song C, Wang Q, Kim K, Mikulski Z, Chandra S, Giles DA, Zahner S Kim PH, Cheroutre H, Colonna M, Kronenberg M 2018 LIGHT-HVEM signaling in innate lymphoid cell subsets protects against enteric bacterial infection. *Cell Host Microbe*. 24:249–60. e4. [PubMed: 30092201]
  27. Gomes MT, Campos PC, Oliveira FS, Corsetti PP, Bortoluci KR, Cunha LD, Zamboni DS, Oliveira SC 2013 Critical role of ASC inflammasomes and bacterial type IV secretion system in caspase-1 activation and host innate resistance to *Brucella abortus* infection. *J. Immunol* 190:3629–3638. [PubMed: 23460746]
  28. Marim FM, Franco MMC, Gomes MTR, Miraglia MC, Giambartolomei GH, Oliveira SC 2017 The role of NLRP3 and AIM2 in inflammasome activation during *Brucella abortus* infection. *Semin. Immunopath* 39: 215–223.
  29. Periasamy S, Le HT, Duffy EB, Chin H, Harton JA 2016 Inflammasome-independent NLRP3 restriction of a protective early neutrophil response to pulmonary tularemia. *PLoS Path.* 12, e1006059.
  30. Rafiei A, Ardestani SK, Kariminia A, Keyhani A, Mohraz M, Amirkhani A 2006 Dominant Th1 cytokine production in early onset of human brucellosis followed by switching towards Th2 along prolongation of disease. *J. Infect* 54:315–324.
  31. Eskandari-Nasab E, Moghadampour M, Hasani SS, Hadadi-fishani M, Mirghanizadeh-Bafghi SA, Asadi-Saghandi A, Zare F, Sadeghi-Kalani B, Ghazali-bina M 2013 Relationship between gamma-interferon gene polymorphisms and susceptibility to brucellosis infection. *Microbiol. Immunol* 57:785–91. [PubMed: 24033468]
  32. Hanot Mambres D, Machelart A, Potemberg G, De Trez C, Ryffel B, Letesson JJ, Muraille E 2016 Identification of immune effectors essential to the control of primary and secondary intranasal infection with *Brucella melitensis* in mice. *J. Immunol* 196:3780–93. [PubMed: 27036913]
  33. Corbel MJ 1997 Brucellosis: an overview. *Emerg. Infect. Dis* 3:213–21. [PubMed: 9204307]
  34. Gross A, Spiesser S, Terraza A, Rouot B, Caron E, Dornand J 1998 Expression and bactericidal activity of nitric oxide synthase in *Brucella suis*-infected murine macrophages. *Infect. Immun* 66:1309–16. [PubMed: 9529047]
  35. Albina JE 1995 On the expression of nitric oxide synthase by human macrophages. Why no NO? *J. Leukoc. Biol* 58:643–9. [PubMed: 7499961]
  36. Knox CD, de Kam PJ, Azer K, Wong P, Ederveen AG, Shevell D, Morabito C, Meehan AG, Liu W, Reynders T, Denef JF, Mitselos A, Jonathan D, Gutstein DE, Mitra K, Sun SY, Lo MM, Cully D, Ali A 2016. Discovery and clinical evaluation of MK-8150, a novel nitric oxide donor with a unique mechanism of nitric oxide release. *J. Am. Heart. Assoc* 2016;5:e003493. [PubMed: 27561272]
  37. Jiang X, Leonard B, Benson R, Baldwin CL 1993 Macrophage control of *Brucella abortus*: role of reactive oxygen intermediates and nitric oxide. *Cell. Immunol.* 151:309–19. [PubMed: 8402938]




**Figure 1. Innate lymphoid cells restrict *Brucella*-induced joint swelling and contribute to IFN- $\gamma$  production**

WT and Rag1<sup>-/-</sup> mice (n=4–5/group) were treated with anti-IFN- $\gamma$  or an isotype control, then infected in both rear footpads with  $1 \times 10^5$  *B. melitensis* 16M **A-B**). Mice were euthanized at day 7 and CFUs were enumerated **A**) while joint swelling was measured throughout the experimental time course **B**). Error bars depict S.D. of the mean. Means at the same timepoint with the same letter are not statistically different from each other as determined by ANOVA followed by Tukey's test. Rag1<sup>-/-</sup> mice (n=5/group) were treated with anti-NK1.1 or anti-CD90, then infected in both rear footpads with  $1 \times 10^5$  *B. melitensis* 16M **C-E**). Joint swelling was measured over time **C**), and on day 7 mice were euthanized and joint IFN- $\gamma$  and tissue CFUs were measured **D-E**). Error bars depict S.D. of the mean. \*P<0.05 as compared to Rag1<sup>-/-</sup>, anti-NK1.1 treated mice. Data in **C-E**) is representative of 2 independent experiments.




**Figure 2. IFN- $\gamma$  deficiency results in severe caspase-1/11 dependent inflammation**

WT and caspase-1/11<sup>-/-</sup> mice were treated with anti-IFN- $\gamma$  or an isotype control, then infected in both rear footpads with  $1 \times 10^5$  *B. melitensis* 16M (A-E). Mice were euthanized at day 7 and joint CFUs and IL-1 $\beta$  levels were enumerated (A,E). Joint swelling was measured throughout the experimental time course (B). At day 7 post-infection, H&E staining on joint sections was conducted and slides were scored for inflammation (C&D). Depicted are representative images (100X) from each group with amplified boxed regions (400X) displayed to their right (C). Data are representative of 3 independent experiments each with 3–5 mice/group except for (D), in which data was combined from 2 experiments with 10–13 mice/group. Error bars depict S.D. of the mean. Means with the same letter at the same timepoint are not statistically different from each other as determined by ANOVA followed by Tukey’s test in (A,B, and E) or ANOVA on Ranks (D).



**Figure 3. IFN- $\gamma$  deficiency results in NLRP3 dependent arthritis following focal, or systemic infection**

WT and NLRP3<sup>-/-</sup> mice (n=4–5/group) were treated with an isotype control or anti-IFN- $\gamma$ , then infected in their rear footpads with  $1 \times 10^5$  *B. melitensis* 16M. Rear ankle joint swelling was measured over time **A-B**). \*P<0.05 as compared to WT mice. Error bars depict S.D. of the mean. Data are representative of 2 independent experiments. WT, caspase-1/11<sup>-/-</sup> and NLRP3<sup>-/-</sup> mice (n=10–11/group) were treated with anti-IFN- $\gamma$  then infected i.p. with  $1 \times 10^5$  *B. melitensis* 16M **C-D**). Joint swelling was measured over the time course of the experiment **C**), and on day 27 post-infection bacterial burdens in joint and spleen were enumerated **D**). Error bars depict S.D. of the mean. Means with the same letter at the same timepoint are not statistically different from each other as determined by ANOVA followed by Tukey's test.



**Figure 4. IFN- $\gamma$ -Dependent Nitric Oxide Suppresses *Brucella*-induced inflammasome activation**  
 WT mice (n=3–4/group) were treated with either anti-IFN- $\gamma$  or an isotype control, then infected in the rear footpads with  $1 \times 10^5$  *B. melitensis* 16M. Mice were euthanized at day 2 post-infection along with naïve animals and RNA was isolated from ankle joints and relative iNOS transcript was measured **A**). Error bars depict S.D. of the mean. \* P<0.05 compared to IgG-treated mice. In a separate experiment, WT mice received anti-IFN- $\gamma$  while other WT mice along with NOS2<sup>-/-</sup> mice received IgG. Mice were infected in the rear footpads with  $1 \times 10^5$  *B. melitensis* 16M **B-D**). Joint swelling was monitored **B**) and mice were euthanized at day 7 post-infection and joint CFUs and IL-1 $\beta$  were enumerated **C-D**). Data are from 4–5 mice/group. Means with the same letter at the same timepoint are not statistically different from each other as determined by ANOVA followed by Tukey’s test. Error bars depict S.D. of the mean. WT bone marrow derived macrophages were infected with *B. melitensis* 16M at an MOI of 100 for 6 hours **E-G**). Media containing increasing doses of SNAP was added after washing of the cells and addition of gentamicin containing media. 24 hours post-infection intracellular *Brucella* burdens were enumerated and IL-1 $\beta$  levels in cell supernatants were determined **E-F**). Cell supernatants and cell lysates were also subjected to Western blot **G**). Data is representative of 2 independent experiments with 3–5 wells/group. Means with the same letter are not statistically different from each other as determined by ANOVA followed by Tukey’s test. Error bars depict S.D. of the mean.